Clinical Trials for Non-Small Cell Lung Cancer

RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory DLL3-expressing or DLL3-prevalent tumors (including SCLC, LCNEC, high-grade neuroendocrine tumors, and select NSCLC/other histologies) receive the DLL3-directed bispecific T‑cell engager tarlatamab plus external-beam radiation, given concurrently or sequentially depending on safety. Key risks include CRS/ICANS; includes extracranial and cranial RT cohorts with allowance for treated/stable brain mets and selected brain lesions.

ClinicalTrials.gov ID: NCT06814496

A Multicenter, Open-label Phase 1/2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-201, an Antibody-drug Conjugate, in Advanced Refractory Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.

ClinicalTrials.gov ID: NCT07145255

A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ALK-rearranged, locally advanced/metastatic NSCLC who have progressed on prior ALK TKI (including post-alectinib or post-lorlatinib) receive oral gilteritinib, a FLT3/ALK tyrosine kinase inhibitor, with intra-patient dose escalation based on tolerability and disease control. Excludes symptomatic CNS/LM disease and significant cardiac/QTc risks; assesses safety with secondary efficacy endpoints (including intracranial response).

ClinicalTrials.gov ID: NCT07140016

A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of Sotorasib Plus Trastuzumab Deruxtecan in Patients With Advanced Non-Small Cell Lung Cancer With a KRASG12C Mutation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic KRAS G12C–mutant NSCLC after prior KRAS G12C inhibitor, immune checkpoint inhibitor, and platinum chemotherapy receive sotorasib, an oral covalent KRAS G12C inhibitor, plus trastuzumab deruxtecan, a HER2-directed topoisomerase I payload antibody-drug conjugate. The study includes dose escalation followed by expansion to assess safety and response, with treated or selected asymptomatic active brain metastases allowed and ILD/pneumonitis excluded.

ClinicalTrials.gov ID: NCT07012031

Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IIIB/IV NSCLC without sensitizing EGFR or ALK/ROS1 alterations receiving first-line standard PD-1/PD-L1–based therapy ± chemotherapy undergo serial ctDNA/biomarker monitoring to guide immunotherapy duration or discontinuation. At progression, biomarker-selected cohorts receive tremelimumab (anti–CTLA-4) plus durvalumab (anti–PD-L1) for STK11/KEAP1-mutant disease or adagrasib (KRAS G12C inhibitor) plus bevacizumab (anti-VEGF) for KRAS G12C-mutant disease.

ClinicalTrials.gov ID: NCT07288034

Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IV NSCLC receiving single-agent pembrolizumab who have both oligoprogressive and nonprogressing lesions undergo SBRT to up to six oligoprogressive sites while continuing pembrolizumab; selected nonprogressing lesions may receive low-dose radiation. They also receive investigational 64Cu-DOTA-pembrolizumab, a radiolabeled PD-1–targeting antibody used for PET imaging before and after radiation rather than as an additional therapeutic dose.

ClinicalTrials.gov ID: NCT07619599

Combination Of Izalontamab Brengitecan And Adagrasib In Advanced KRAS G12Ci-Refractory Non-Small Cell Lung Cancer - The IZA-A Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, incurable KRAS G12C-mutant NSCLC that has progressed on a prior KRAS G12C inhibitor receive adagrasib, a KRAS G12C inhibitor, plus investigational izalontamab brengitecan, an EGFR/HER3-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload. Eligible patients have received 1–3 prior lines of therapy and have ECOG performance status 0–1.

ClinicalTrials.gov ID: NCT07382726

A Phase 1b Clinical Study of NXP900 in Combination With Lorlatinib in Subjects With Advanced, ALK-positive, Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic ALK-positive NSCLC who have received and tolerated lorlatinib are treated with lorlatinib plus escalating doses of NXP900, an oral SRC-family kinase inhibitor targeting YES1 and SRC. The study particularly addresses disease progression or acquired resistance during lorlatinib treatment.

ClinicalTrials.gov ID: NCT07784959

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced NSCLC unsuitable for definitive therapy or metastatic NSCLC receive oral ABSK112, an investigational brain-penetrant kinase inhibitor designed to target EGFR exon 20 insertions while relatively sparing wild-type EGFR. Dose expansion requires a documented EGFR exon 20 insertion; patients with EGFR C797S mutations are excluded.

ClinicalTrials.gov ID: NCT06225804

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial involves patients with oligoprogressive non-small cell lung cancer who previously received first-line systemic therapies, evaluating the safety of adding the antimicrobial agent vancomycin to precision hypofractionated radiation therapy. Vancomycin, known for inhibiting bacterial cell wall synthesis, is used here to potentially reduce infections and modulate the immune response.

ClinicalTrials.gov ID: NCT03546829